<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034435</url>
  </required_header>
  <id_info>
    <org_study_id>131139</org_study_id>
    <nct_id>NCT02034435</nct_id>
  </id_info>
  <brief_title>Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism</brief_title>
  <official_title>Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim 1.Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone&#xD;
      system impairs glycemic control via effects on insulin sensitivity and insulin secretion.&#xD;
&#xD;
      Aim 2. Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone&#xD;
      system impairs insulin secretion and insulin sensitivity via an mineralocorticoid-receptor&#xD;
      dependent mechanism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In aim 1 subjects are randomized to cross over between an 8 day high salt and 8 day low salt&#xD;
      diet and assessments are made.&#xD;
&#xD;
      In aim 2, subjects are randomized to a 2x2 cross over study with an 8 day low salt diet and&#xD;
      either eplerenone 50mg or amlodipine 5mg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Secretion</measure>
    <time_frame>After 8 days of diet or drug</time_frame>
    <description>Hyperglycemic clamp- acute insulin response (AIR) during time 0-10 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>after 8 days of diet or medication</time_frame>
    <description>Hyperinsulinemic clamp- glucose infusion rate during insulin administration</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Aim1-Low Sodium then High Sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be provided with a low sodium diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.&#xD;
Participants will be given low sodium diet (50mEq/d) and Placebo tablets for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Salt tables (150mEq) for 8days and assessments will be made.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim 1-high salt diet then low salt diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.&#xD;
Participants will be given low sodium diet (50mEq/d) and Salt tables (150mEq) for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Placebo tablets for 8days and assessments will be made.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aim2- low salt diet and epleronone then amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects on a low salt diet will receive Epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with Amlodipine 5mg for 8days and assessments will be made.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aim2- low salt diet and amlodipine then epleronone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects on a low salt diet will receive Amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with Epleronone 50mg for 8days and assessments will be made.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Salt diet plus Placebo tablet</intervention_name>
    <arm_group_label>Aim 1-high salt diet then low salt diet</arm_group_label>
    <arm_group_label>Aim1-Low Sodium then High Sodium</arm_group_label>
    <arm_group_label>Aim2- low salt diet and epleronone then amlodipine</arm_group_label>
    <arm_group_label>aim2- low salt diet and amlodipine then epleronone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low Sodium diet plus Salt tablet</intervention_name>
    <arm_group_label>Aim 1-high salt diet then low salt diet</arm_group_label>
    <arm_group_label>Aim1-Low Sodium then High Sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epleronone</intervention_name>
    <description>50mg daily</description>
    <arm_group_label>Aim2- low salt diet and epleronone then amlodipine</arm_group_label>
    <arm_group_label>aim2- low salt diet and amlodipine then epleronone</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>5mg daily</description>
    <arm_group_label>Aim2- low salt diet and epleronone then amlodipine</arm_group_label>
    <arm_group_label>aim2- low salt diet and amlodipine then epleronone</arm_group_label>
    <other_name>Norvasc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ambulatory subjects, 18 to 70 years of age, inclusive&#xD;
&#xD;
          2. For female subjects, the following conditions must be met:&#xD;
&#xD;
               1. postmenopausal status for at least 1 year, or&#xD;
&#xD;
               2. status-post surgical sterilization, or&#xD;
&#xD;
               3. if of childbearing potential, utilization of adequate birth control and&#xD;
                  willingness to undergo urine beta-hcg testing prior to drug treatment and on&#xD;
                  every study day.&#xD;
&#xD;
          3. Metabolic Syndrome as defined by the presence of &gt; 3 of the following:&#xD;
&#xD;
               1. Systolic Blood Pressure &gt; 130 mm Hg OR Diastolic Blood Pressure &gt; 85 mm Hg.&#xD;
&#xD;
               2. Glucose Intolerance (Fasting Plasma Glucose â‰¥ 100 mg/dL)&#xD;
&#xD;
               3. Increased triglyceride level &gt; 150mg/dL (1.7mmol/L)&#xD;
&#xD;
               4. Decreased levels of HDL cholesterol (For males, less than 40 mg/dL; For females,&#xD;
                  less than 50 mg/dL)&#xD;
&#xD;
               5. Waist circumference (For males, greater than 40 inches; For females, greater than&#xD;
                  35 inches)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. type 1 Diabetes&#xD;
&#xD;
          2. Type II Diabetes&#xD;
&#xD;
          3. Impaired renal function&#xD;
&#xD;
          4. Prior allergies to medications used in the study protocol&#xD;
&#xD;
          5. Screening plasma potassium &gt;5.5 mmol/L or sodium &lt;135 mmol/L&#xD;
&#xD;
          6. Cardiovascular disease&#xD;
&#xD;
          7. Use of hormone replacement therapy&#xD;
&#xD;
          8. Breast-feeding&#xD;
&#xD;
          9. Treatment with anticoagulants&#xD;
&#xD;
         10. History of serious neurologic disease&#xD;
&#xD;
         11. History or presence of immunological or hematological disorders&#xD;
&#xD;
         12. Diagnosis of asthma requiring use of inhaled beta agonist&#xD;
&#xD;
         13. Clinically significant gastrointestinal impairment&#xD;
&#xD;
         14. Impaired hepatic function&#xD;
&#xD;
         15. Hematocrit &lt;35%&#xD;
&#xD;
         16. Any underlying or acute disease requiring regular medication which could possibly pose&#xD;
             a threat to the subject or make implementation of the protocol or interpretation of&#xD;
             the study results difficult, such as arthritis treated with non-steroidal&#xD;
             antiinflammatory drugs&#xD;
&#xD;
         17. Treatment with chronic systemic glucocorticoid therapy&#xD;
&#xD;
         18. Treatment with lithium salts&#xD;
&#xD;
         19. History of alcohol or drug abuse&#xD;
&#xD;
         20. Treatment with any investigational drug in the 1 month preceding&#xD;
&#xD;
         21. Mental conditions rendering the subject unable to understand the nature, scope and&#xD;
             possible consequences of the study&#xD;
&#xD;
         22. Inability to comply with the protocol, e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikelihood of completing the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James M Luther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 9, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2014</study_first_posted>
  <results_first_submitted>December 6, 2020</results_first_submitted>
  <results_first_submitted_qc>December 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 31, 2020</results_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>James Matt Luther</investigator_full_name>
    <investigator_title>M.D., MSCI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT02034435/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aim1-Low Sodium Then High Sodium</title>
          <description>Subjects will be provided with a low sodium diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.&#xD;
Participants will be given low sodium diet (50mEq/d) and Placebo tablets for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Salt tables (150mEq) for 8days and assessments will be made.&#xD;
Low Salt diet plus Placebo tablet&#xD;
Low Sodium diet plus Salt tablet</description>
        </group>
        <group group_id="P2">
          <title>Aim 1-High Sodium Then Low Sodium</title>
          <description>Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content.&#xD;
Participants will be given low sodium diet (50mEq/d) and Salt tables (150mEq) for 8 days and assessments will be made, washout and then cross over to a low sodium diet (50mEq/d) plus Placebo tablets for 8days and assessments will be made.&#xD;
Low Salt diet plus Placebo tablet&#xD;
Low Sodium diet plus Salt tablet</description>
        </group>
        <group group_id="P3">
          <title>Aim2- Low Sodium Diet and Epleronone Then Amlodipine</title>
          <description>Subjects on a low salt diet will receive Epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with Amlodipine 5mg for 8days and assessments will be made.&#xD;
Low Salt diet plus Placebo tablet&#xD;
Epleronone: 50mg daily&#xD;
Amlodipine: 5mg daily</description>
        </group>
        <group group_id="P4">
          <title>Aim2- Low Sodium Diet and Amlodipine Then Epleronone</title>
          <description>Subjects on a low salt diet will receive Amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with Epleronone 50mg for 8days and assessments will be made.&#xD;
Low Salt diet plus Placebo tablet&#xD;
Epleronone: 50mg daily&#xD;
Amlodipine: 5mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Aim 1</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Aim 2</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequate IV access</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aim 1</title>
          <description>Low Sodium and High Sodium diet crossover</description>
        </group>
        <group group_id="B2">
          <title>Aim 2</title>
          <description>Eplerenone and Amlodipine crossover</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="29" upper_limit="56"/>
                    <measurement group_id="B2" value="46" lower_limit="43" upper_limit="56"/>
                    <measurement group_id="B3" value="45" lower_limit="40" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Secretion</title>
        <description>Hyperglycemic clamp- acute insulin response (AIR) during time 0-10 minutes</description>
        <time_frame>After 8 days of diet or drug</time_frame>
        <population>Participants with metabolic syndrome</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 1- Low Sodium</title>
            <description>Low Sodium diet (50mEq/d)</description>
          </group>
          <group group_id="O2">
            <title>Aim 1- High Sodium</title>
            <description>Low sodium diet (50mEq/d) plus sodium tablet (150 mEq/d)</description>
          </group>
          <group group_id="O3">
            <title>Aim 2- Eplerenone</title>
            <description>Low sodium diet (50mEq/d) plus Eplerenone</description>
          </group>
          <group group_id="O4">
            <title>Aim 2- Amlodipine</title>
            <description>Low sodium diet (50mEq/d) plus Amlodipine</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Secretion</title>
          <description>Hyperglycemic clamp- acute insulin response (AIR) during time 0-10 minutes</description>
          <population>Participants with metabolic syndrome</population>
          <units>uU/mL*10min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.1" lower_limit="186.9" upper_limit="369.4"/>
                    <measurement group_id="O2" value="234.7" lower_limit="161.3" upper_limit="479.7"/>
                    <measurement group_id="O3" value="330.8" lower_limit="268.2" upper_limit="481.5"/>
                    <measurement group_id="O4" value="300.4" lower_limit="177.8" upper_limit="477.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity</title>
        <description>Hyperinsulinemic clamp- glucose infusion rate during insulin administration</description>
        <time_frame>after 8 days of diet or medication</time_frame>
        <population>Participants with metabolic syndrome</population>
        <group_list>
          <group group_id="O1">
            <title>Aim 1- Low Sodium</title>
            <description>Low Sodium diet (50mEq/d)</description>
          </group>
          <group group_id="O2">
            <title>Aim 1- High Sodium</title>
            <description>Low sodium diet (50mEq/d) plus sodium tablet (150 mEq/d)</description>
          </group>
          <group group_id="O3">
            <title>Aim 2- Eplerenone</title>
            <description>Low sodium diet (50mEq/d) plus Eplerenone</description>
          </group>
          <group group_id="O4">
            <title>Aim 2- Amlodipine</title>
            <description>Low sodium diet (50mEq/d) plus Amlodipine</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Hyperinsulinemic clamp- glucose infusion rate during insulin administration</description>
          <population>Participants with metabolic syndrome</population>
          <units>mg/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="5.5" upper_limit="7.6"/>
                    <measurement group_id="O2" value="6.9" lower_limit="6.1" upper_limit="7.6"/>
                    <measurement group_id="O3" value="6.4" lower_limit="5.8" upper_limit="8.2"/>
                    <measurement group_id="O4" value="6.3" lower_limit="5.4" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Monitoring during 1 week of intervention/drug, washout period, and during cross-over to 1 week of remaining intervention/drug. Monitoring for adverse events continued up to 2 weeks after study completion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aim 1- Low Sodium</title>
          <description>Low Sodium diet (50mEq/d)</description>
        </group>
        <group group_id="E2">
          <title>Aim 1- High Sodium</title>
          <description>Low sodium diet (50mEq/d) plus sodium tablet (150 mEq/d)</description>
        </group>
        <group group_id="E3">
          <title>Aim 2- Eplerenone</title>
          <description>Low sodium diet (50mEq/d) plus Eplerenone</description>
        </group>
        <group group_id="E4">
          <title>Aim 2- Amlodipine</title>
          <description>Low sodium diet (50mEq/d) plus Amlodipine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Low glucose</sub_title>
                <description>low glucose after clamp, resolved</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>discomfort with swallowing pill</sub_title>
                <description>temporary discomfort when swallowing tablets</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>rectal fissure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>viral illness</sub_title>
                <description>Unrelated viral or other illness</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>IV infiltration or malfunction</sub_title>
                <description>bruising, swelling, or pain at IV site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cramp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache during study</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>numbness</sub_title>
                <description>temporary numbess in hand, resolved spontaneously</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James M. Luther, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>(615) 936-3420</phone>
      <email>james.luther@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

